And here's the thing, some of the people who agree with Sean Tu, they aren't who you'd expect.

Yeah, Amarin would have you believe that doctors pay attention to investor relations calls in making their prescribing decisions.

Normal things generic companies say all the time, but now-

The focus on what's printed on the label and what's being said in the market, what your detailers are saying to physicians, what you're telling investors, a bigger scope of activities could be used to find infringement.